These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 15718420)
21. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097 [TBL] [Abstract][Full Text] [Related]
22. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449 [TBL] [Abstract][Full Text] [Related]
24. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343 [TBL] [Abstract][Full Text] [Related]
25. Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. Chung KY; Morrone G; Schuringa JJ; Wong B; Dorn DC; Moore MA Blood; 2005 Jan; 105(1):77-84. PubMed ID: 15242879 [TBL] [Abstract][Full Text] [Related]
26. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia]. Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437 [TBL] [Abstract][Full Text] [Related]
27. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Kelly LM; Yu JC; Boulton CL; Apatira M; Li J; Sullivan CM; Williams I; Amaral SM; Curley DP; Duclos N; Neuberg D; Scarborough RM; Pandey A; Hollenbach S; Abe K; Lokker NA; Gilliland DG; Giese NA Cancer Cell; 2002 Jun; 1(5):421-32. PubMed ID: 12124172 [TBL] [Abstract][Full Text] [Related]
28. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo. Nabinger SC; Li XJ; Ramdas B; He Y; Zhang X; Zeng L; Richine B; Bowling JD; Fukuda S; Goenka S; Liu Z; Feng GS; Yu M; Sandusky GE; Boswell HS; Zhang ZY; Kapur R; Chan RJ Leukemia; 2013 Feb; 27(2):398-408. PubMed ID: 23103841 [TBL] [Abstract][Full Text] [Related]
29. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Thiede C; Steudel C; Mohr B; Schaich M; Schäkel U; Platzbecker U; Wermke M; Bornhäuser M; Ritter M; Neubauer A; Ehninger G; Illmer T Blood; 2002 Jun; 99(12):4326-35. PubMed ID: 12036858 [TBL] [Abstract][Full Text] [Related]
30. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056 [TBL] [Abstract][Full Text] [Related]
31. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia]. Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475 [TBL] [Abstract][Full Text] [Related]
32. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077 [TBL] [Abstract][Full Text] [Related]
33. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Yamamoto Y; Kiyoi H; Nakano Y; Suzuki R; Kodera Y; Miyawaki S; Asou N; Kuriyama K; Yagasaki F; Shimazaki C; Akiyama H; Saito K; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Saito H; Ueda R; Ohno R; Naoe T Blood; 2001 Apr; 97(8):2434-9. PubMed ID: 11290608 [TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia. Kang HJ; Hong SH; Kim IH; Park BK; Han KS; Cho HI; Shin HY; Ahn HS Leuk Res; 2005 Jun; 29(6):617-23. PubMed ID: 15863200 [TBL] [Abstract][Full Text] [Related]
35. Leukemogenic potency of the novel FLT3-N676K mutant. Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877 [TBL] [Abstract][Full Text] [Related]
36. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Li L; Piloto O; Nguyen HB; Greenberg K; Takamiya K; Racke F; Huso D; Small D Blood; 2008 Apr; 111(7):3849-58. PubMed ID: 18245664 [TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Yanada M; Matsuo K; Suzuki T; Kiyoi H; Naoe T Leukemia; 2005 Aug; 19(8):1345-9. PubMed ID: 15959528 [TBL] [Abstract][Full Text] [Related]
38. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. Scholl S; Krause C; Loncarevic IF; Müller R; Kunert C; Wedding U; Sayer HG; Clement JH; Höffken K J Lab Clin Med; 2005 Jun; 145(6):295-304. PubMed ID: 15976757 [TBL] [Abstract][Full Text] [Related]
39. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Scheijen B; Ngo HT; Kang H; Griffin JD Oncogene; 2004 Apr; 23(19):3338-49. PubMed ID: 14981546 [TBL] [Abstract][Full Text] [Related]
40. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]